PROGRAM CANCER AGAINST ITSELF
LIVE

Serial Number

99699133

Owner

Earli Inc.

Attorney

Ted D. Karr

Filing Date

Mar 12, 2026

Add to watchlist:

No watchlists yet
View on USPTO

PROGRAM CANCER AGAINST ITSELF Trademark

Serial Number: 99699133

PROGRAM CANCER AGAINST ITSELF is a trademark filed by Earli Inc. on March 12, 2026. The trademark is classified under Class 5 (Pharmaceuticals), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Earli Inc. (9 trademarks)

Mountain View, CA 94022

Entity Type: 03

Trademark Details

Filing Date

March 12, 2026

Registration Date

Not Registered

Goods & Services

Medical services for the prevention of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for detecting cancer; Medical services for the detection of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for detection of cancer; Medical services for the localization of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for the localization of cancer; Medical services for the therapy of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for treating cancer; Medical services for the prevention of cancer in animals, namely, medical assay processing provided by medical laboratories and medical analysis services for detecting cancer; Medical services for the detection of cancer in animals, namely, medical assay processing provided by medical laboratories and medical analysis services for detection of cancer; Medical services for the therapy of cancer in animals, namely, medical assay processing provided by medical laboratories and medical analysis services for the treatment of cancer

Products for the prevention of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the detection of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the localization of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for localization of cancer; Products for the therapy of cancer in humans, namely, pharmaceutical products to express a treatment agent for treating cancer; Products for the prevention of cancer in animals, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the detection of cancer in animals, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the therapy of cancer in animals, namely, pharmaceutical products to express a treatment agent for treating cancer

Filing History

NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 28, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jun 28, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jun 28, 2026 CNRT
ASSIGNED TO EXAMINER
Jun 22, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 12, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 12, 2026 NWOS
NEW APPLICATION ENTERED
Mar 12, 2026 NWAP